Abstract 1126: CLSP-1025, a first-in-class precision T cell engager for the treatment of p53 mutant cancers
Michael F. Maloney, Kristen McEachern, Veselin S. Dobrev, Amanda Ford, Lauren C. Harshman(Dana-Farber Cancer Institute), Cláudia Regina Batista de Souza, Alec R. Andrews, Julie DeSander, Gillian A. Kingsbury(Bicycle Therapeutics (United Kingdom)), Justina X. Caushi(Aeras), Kate L. Stokes, Vipin Suri, David Orlando(AVEO Oncology (United States)), Ronald J. Copeland(Johns Hopkins University), Kaleigh Krapfl, Madison Curtis Siok, Anthony S. Gizzi, Shannon Devens, James B. Bingham
Cited by 0
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Glycomics Hits the Big Time
|Cell|2010|640
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
|Nature|2021|546
O-GlcNAc signaling: a metabolic link between diabetes and cancer?
|Trends in Biochemical Sciences|2010|341